Patients who have private or commercial insurance may be eligible for a savings offer.
Patients who have private or commercial insurance may be eligible for a savings offer.
Patients who have private or commercial insurance with coverage may be eligible to pay as little as $0 per year for their supply of Sogroya® (with an annual maximum cap of $3,000).a
Direct patients to visit SogroyaSavings.com to get this savings offer.
Patients who have private or commercial insurance with coverage may be eligible to pay as little as $0 per year for their supply of Norditropin® (with an annual maximum cap of $1,500).a
Direct patients to visit NorditropinSavings.com to get this savings offer.
Norditropin® is contraindicated in patients with:
Norditropin® (somatropin) injection is indicated for the treatment of pediatric patients with:
Norditropin® is also indicated for the replacement of endogenous GH in adults with growth hormone deficiency (GHD)
Norditropin® is contraindicated in patients with:
Please click here for Prescribing Information.
Sogroya® is contraindicated in patients with:
Sogroya® (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg is indicated for the:
Sogroya® is contraindicated in patients with:
Please click here for Sogroya® Prescribing Information.
Norditropin® is contraindicated in patients with:
Norditropin® (somatropin) injection is indicated for the treatment of pediatric patients with:
Norditropin® is also indicated for the replacement of endogenous GH in adults with growth hormone deficiency (GHD)
Norditropin® is contraindicated in patients with:
Please click here for Prescribing Information.
Sogroya® is contraindicated in patients with:
Sogroya® (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg is indicated for the:
Sogroya® is contraindicated in patients with:
Please click here for Sogroya® Prescribing Information.